Sangamo BioSciences to Host Conference Call to Discuss Results From Phase 2b Diabetic Neuropathy Trial Monday 8:30am
Sangamo BioSciences (NASDAQ: SGMO) today announced that the company will hold a teleconference and webcast at 8:30 am ET, on Monday, October 3, 2011, to discuss results of the Phase 2b clinical trial from its ZFP Therapeutic program to develop SB-509 as a treatment for diabetic neuropathy. A press release summarizing the data from the trial will be issued at 7:00 am ET on Monday prior to this call.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.